A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation.

A technique called whole-exome sequencing (WES) has been used for the first time at Vanderbilt University to identify new genetic variations associated with a common disease — a heart rhythm abnormality called atrial fibrillation (AF).

Variation in the gene for the beta-1 adrenergic receptor increases the risk that a patient will have an abnormal heart rhythm after cardiac surgery.

A genetic variant that increases risk for atrial fibrillation also impacts the response to a common therapy for the heart rhythm disorder.

A rare genetic variant that occurs more commonly in families of patients with atrial fibrillation (AF) may be a key to better understanding this common and potentially life threatening condition, Vanderbilt University researchers reported this week.

Individuals with atrial fibrillation who have a particular genetic variant respond better to rate control therapy.